Literature DB >> 24771229

Transient abnormal myelopoiesis in a phenotypically normal newborn with polyclonal trisomy 21.

Francesco Corazza1, Annalisa Astolfi, Virginia Libri, Monica Franzoni, Salvatore Serravalle, Rosina Alessandroni, Fraia Melchionda, Andrea Pession.   

Abstract

We report a rare case of transient abnormal myelopoiesis (TAM) in a phenotypically normal neonate. The presence of a palpable hepatomegaly prompted in-depth laboratory tests, which revealed the presence of severe hyperleukocytosis, with blast cells present in a peripheral blood smear. Although no signs of Down syndrome were present, we suspected TAM. Further analysis identified a mutation in GATA1 along with the unique finding of two different trisomic cell lines, detected upon karyotyping; one with trisomy 21 only, and one with trisomies 21 and 22, which was present in a subpopulation of peripheral blood cells. These genetic abnormalities disappeared by the age of 6 months. The presence of two different trisomic clones may be an evidence of the polyclonal nature of TAM in this patient.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24771229     DOI: 10.1007/s12185-014-1584-0

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.319


  17 in total

1.  Transient abnormal myelopoiesis in a cytogenetically normal neonate.

Authors:  Kentaro Yanase; Keisuke Kato; Nobuko Katayama; Yoko Mouri; Chie Kobayashi; Junko Shiono; Masakazu Abe; Ai Yoshimi; Kazutoshi Koike; Jun-Ichi Arai; Masahiro Tsuchida
Journal:  Int J Hematol       Date:  2010-09-23       Impact factor: 2.490

2.  Incidence and clinical implications of GATA1 mutations in newborns with Down syndrome.

Authors:  Sharon R Pine; Qianxu Guo; Changhong Yin; Somasundaram Jayabose; Charlotte M Druschel; Claudio Sandoval
Journal:  Blood       Date:  2007-06-18       Impact factor: 22.113

Review 3.  Biology and management of transient abnormal myelopoiesis (TAM) in children with Down syndrome.

Authors:  Anindita Roy; Irene Roberts; Paresh Vyas
Journal:  Semin Fetal Neonatal Med       Date:  2012-03-14       Impact factor: 3.926

Review 4.  Contribution of GATA1 dysfunction to multi-step leukemogenesis.

Authors:  Ritsuko Shimizu; Masayuki Yamamoto
Journal:  Cancer Sci       Date:  2012-10-10       Impact factor: 6.716

5.  Clonal selection in xenografted TAM recapitulates the evolutionary process of myeloid leukemia in Down syndrome.

Authors:  Satoshi Saida; Ken-ichiro Watanabe; Aiko Sato-Otsubo; Kiminori Terui; Kenichi Yoshida; Yusuke Okuno; Tsutomu Toki; RuNan Wang; Yuichi Shiraishi; Satoru Miyano; Itaru Kato; Tatsuya Morishima; Hisanori Fujino; Katsutsugu Umeda; Hidefumi Hiramatsu; Souichi Adachi; Etsuro Ito; Seishi Ogawa; Mamoru Ito; Tatsutoshi Nakahata; Toshio Heike
Journal:  Blood       Date:  2013-03-12       Impact factor: 22.113

6.  Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children's Oncology Group Study A2971.

Authors:  Alan S Gamis; Todd A Alonzo; Robert B Gerbing; Joanne M Hilden; April D Sorrell; Mukta Sharma; Thomas W Loew; Robert J Arceci; Dorothy Barnard; John Doyle; Gita Massey; John Perentesis; Yaddanapudi Ravindranath; Jeffrey Taub; Franklin O Smith
Journal:  Blood       Date:  2011-08-17       Impact factor: 22.113

7.  Distinct clones are associated with the development of transient myeloproliferative disorder and acute megakaryocytic leukemia in a patient with Down syndrome.

Authors:  Hirokazu Kanegane; Sayaka Watanabe; Keiko Nomura; Gang Xu; Etsuro Ito; Toshio Miyawaki
Journal:  Int J Hematol       Date:  2007-10       Impact factor: 2.490

8.  Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome.

Authors:  Joshua Wechsler; Marianne Greene; Michael A McDevitt; John Anastasi; Judith E Karp; Michelle M Le Beau; John D Crispino
Journal:  Nat Genet       Date:  2002-08-12       Impact factor: 38.330

9.  Transient myeloproliferative disorder in neonates with and without Down syndrome: a tale of 2 syndromes.

Authors:  Nataly Apollonsky; Ashok Shende; Ihsane Ouansafi; Judith Brody; Mark Atlas; Banu Aygun
Journal:  J Pediatr Hematol Oncol       Date:  2008-11       Impact factor: 1.289

10.  Natural history of GATA1 mutations in Down syndrome.

Authors:  Momin Ahmed; Alexander Sternberg; Georgina Hall; Angela Thomas; Owen Smith; Aengus O'Marcaigh; Robert Wynn; Richard Stevens; Michael Addison; Derek King; Barbara Stewart; Brenda Gibson; Irene Roberts; Paresh Vyas
Journal:  Blood       Date:  2003-12-04       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.